Company Email Format Management

BerGenBio ASA

Biotechnology Research Bergen, Vestland, No 20 employees

Employees: 20
Contacts: 2
Emails: 2

bergenbio.com LinkedIn Crunchbase

BerGenBio ASA Overview

Headquarters: Bergen, Vestland, No
Website: bergenbio.com
Industry: Biotechnology Research
Employees: 20
Founded: 2008
Funding: 23.1M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Drug discovery Drug target discovery Aggressive drug-resistant cancer AXL oncology acute myeloid leukaemia Non-small cell lung cancer

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance – the cause of approximately 90 percent of cancer deaths. Inhibition of AXL kinase activity represents a novel approach to addressing a key mechanism in the evolution of cancer cell malignancy and aggressiveness, offering an opportunity to create important new therapeutic options for cancer patients.

BerGenBio ASA Contact Details

People in AeroLeads: 3
With contact data: 2
Email contacts: 2; 66.7% coverage

BerGenBio ASA Org Chart

Sample employees and titles

Name	Title	Location	Contact
Cristina Oliva	Chief Medical Officer at Bergenbio	Reading, England, United Kingdom	Email
Ann-Tove Kongsnes	Deputy Ceo/investment Director	Trondheim, Trøndelag, Norway	Email
David Colpman	Independent Board Member and Business		View